ArticleScientific reports2025
SPC25 as a prognostic and immune-related biomarker in lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cross-tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Comprehensive Pan-Cancer Analysis Reveals RNF20 as a Candidate Prognostic and Diagnostic Biomarker.Bioinformatics and biology insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the development of human cancers, alterations in the process of cell mitosis frequently play a role. In recent years, an increasing number of researchers have focused on the phenomenon of cancer resulting from kinetochore-microtubule attachment imbalance.Spindle pole body component 25 (SPC25) is essential for the organization of the spindle devices and chromosome separation. SPC25 has a significant role in the occurrence and development of malignant tumors, but its role in lung adenocarcinoma has not been established. This study utilizes the TCGA database and centrosome assembly checkpoint specialized resources to explore the molecular mechanisms of lung adenocarcinoma and its interaction with the immune system. By using the "limma" and "survival" R software packages and Venn diagram analysis, we identify differentially expressed mRNAs that are associated with lung adenocarcinoma prognosis and play a role in centrosome assembly checkpoint regulation, and determine SPC25 as the target gene. We use the "pROC" software package to draw ROC curves to evaluate its diagnostic potential, perform chi-square tests and logistic regression models to analyze its relationship with clinical pathological features. Cox regression analysis deepens our understanding of its prognostic evaluation role, and enrichment analysis reveals its biological functions and signaling pathways. We also explore the correlation between SPC25 and lung adenocarcinoma immune infiltration by combining ssGSEA and Spearman analysis. The objective of this study was to investigate the association between SPC25 and the prognosis as well as immune infiltration in lung adenocarcinoma, aiming to establish a crucial molecular foundation for early non-invasive diagnosis and immunotherapy of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.